



## Supplementary Data of Consolidated Financial Statements for the Second Quarter Ended September 30, 2018

October 31, 2018  
NITTO DENKO CORPORATION

### CONTENTS

	Page
◆ Business Results	1
◆ Segment Information	2
◆ Segment Information By Geographic Area	3
<u>Revenue to customers outside Japan</u>	

(Note) In the amounts of money in this material, fractions below the shown figures are omitted.  
Percentages(%) are rounded to the nearest decimal point.

Forward-looking statements such as those relating to earnings forecasts and other projections contained in this material are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

## Business Results

(Unit: Billions of yen, ( ) : % of change from the previous quarter)

		Revenue	Operating Income	Net Income
2Q FY2018 (Jul.-Sep.)	Results	210.4	24.8	18.0
		(-6.8)	(-34.5)	(-33.9)

(Unit: Billions of yen, ( ) : % of change from the previous year)

		Revenue	Operating Income	Net Income
1H FY2018 (Apr.-Sep.)	Results	402.5	51.3	35.1
		(-5.7)	(-24.7)	(-26.1)

(Unit: Billions of yen, ( ) : % of change from the previous forecasts)

		Revenue	Operating Income	Net Income
Forecasts of FY2018	As of Apr 27	860.0	135.0	100.0
	As of Oct 31	830.0 (-3.5)	115.0 (-14.8)	84.0 (-16.0)

(Billions of yen)

(Yen/1US\$)

		Depreciation	Capital Investment	R&D Expenditures	Exchange Rate
1H, FY2018 (Apr.-Sep.)	Results	23.1	38.0	15.5	109.3
Forecasts of FY2018	As of Apr 27	48.5	70.0	33.0	
	As of Oct 31	47.5	70.0	33.0	

### Topics

#### ◆ New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN®

Sumitomo Dainippon Pharma Co., Ltd. announces that it submitted a new drug application in Japan for a transdermal patch formulation of LONASEN® (generic name: blonanserin, hereinafter, "blonanserin"), an atypical antipsychotic agent, which is currently being developed jointly with Nitto.

Blonanserin has the benefits characteristic of patch formulations, namely, it is easy to check medication status visually, and susceptibility to the effects of food is low. This is very helpful to patients for whom oral administration can be problematic, for example, due to difficulty in swallowing. If blonanserin is approved, the two companies will be able to provide patients affected by schizophrenia with a treatment option that has a novel administration route.

# Segment Information

## Revenue & Operating Income by Segment

(Yen in Millions)

		FY2017 Results *					FY2018 Results					Forecasts as of Oct 31	
		2Q, FY2017	1H, FY2017	3Q, FY2017	4Q, FY2017	FY2017	1Q, FY2018	2Q, FY2018		1H, FY2018		FY2018	
		Revenue	Revenue	Revenue	Revenue	Revenue	Revenue	Revenue	Y-o-Y(%)	Revenue	Y-o-Y(%)	Revenue	Y-o-Y(%)
Industrial Tape	Functional Base Products	46,091	85,776	46,510	41,543	173,830	41,796	46,247	100.3	88,043	102.6	184,000	105.9
	Transportation	41,478	80,604	43,511	40,926	165,042	40,238	41,105	99.1	81,343	100.9	165,000	100.0
	Revenue	87,570	166,380	90,021	82,469	338,872	82,034	87,352	99.8	169,387	101.8	349,000	103.0
	Operating Income	9,702	17,275	10,008	7,692	34,976	6,702	8,143	83.9	14,846	85.9	36,000	102.9
Optronics	Information Fine Materials	117,072	216,905	123,061	84,186	424,153	84,211	103,677	88.6	187,888	86.6	393,000	92.7
	Flexible Printed Circuits	10,380	20,759	11,028	10,251	42,038	10,633	11,128	107.2	21,762	104.8	44,200	105.1
	Processing Materials	6,416	12,108	6,290	6,040	24,439	5,630	5,817	90.7	11,448	94.5	24,800	101.5
	Revenue	133,869	249,773	140,380	100,478	490,632	100,475	120,623	90.1	221,098	88.5	462,000	94.2
	Operating Income	28,811	50,175	34,655	7,084	91,916	13,041	18,519	64.3	31,561	62.9	80,000	87.0
Life Science	Revenue	7,101	15,364	5,438	15,367	36,171	11,195	5,536	78.0	16,731	108.9	28,000	77.4
	Operating Income	222	1,726	-1,099	5,302	5,929	4,866	-1,811	-	3,055	177.0	500	8.4
Others	Revenue	6,527	12,825	6,345	6,108	25,279	6,287	6,090	93.3	12,378	96.5	25,000	98.9
	Operating Income	19	173	-32	-334	-192	-346	-431	-	-777	-	-1,000	-
Elimination & Corporate	Revenue	-9,203	-17,291	-9,260	-8,140	-34,693	-7,877	-9,186	-	-17,064	-	-34,000	-
	Operating Income	-853	-1,109	-2,511	-3,285	-6,905	2,276	403	-	2,680	-	-500	-
Total	Revenue	225,865	427,052	232,925	196,283	856,262	192,115	210,416	93.2	402,532	94.3	830,000	96.9
	Operating Income	37,902	68,242	41,020	16,459	125,722	26,540	24,824	65.5	51,365	75.3	115,000	91.5

\* From fiscal year 2018, we have changed the attribution of a group company internally in "Industrial Tape", and the change has also been reflected in the figures for the fiscal year 2017.

## Segment Information by Geographic Area

(Yen in Millions)

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
1H 2017	Revenue to Outside Customers	97,468	38,296	21,494	269,793	427,052	-	427,052
	Inter-segment Revenue or Transfers	201,703	4,673	2,031	16,200	224,608	-224,608	-
	Revenue Total	299,171	42,969	23,525	285,994	651,661	-224,608	427,052
	Operating Income	48,970	5,136	1,839	13,643	69,590	-1,348	68,242

		Japan	Americas	Europe	Asia & Oceania	Total	Eliminations & Corporate	Consolidated Total
1H 2018	Revenue to Outside Customers	95,330	39,488	22,596	245,117	402,532	-	402,532
	Inter-segment Revenue or Transfers	178,604	5,357	2,168	16,168	202,298	-202,298	-
	Revenue Total	273,934	44,845	24,765	261,285	604,830	-202,298	402,532
	Operating Income	34,184	6,284	1,838	10,059	52,366	-1,001	51,365

Note: Major countries or regions excluding Japan are represented as follows:  
 Americas : U.S.A., Mexico, Brazil  
 Europe : Belgium, France, Germany, Sweden, Turkey  
 Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand

## Revenue to Customers Outside Japan

(Yen in Millions)

		Americas	Europe	Asia & Oceania	Others	Total
1H 2017	Revenue to Customers Outside Japan	35,044	22,247	257,810	516	315,619
	Consolidated Revenue	/				427,052
	Ratio to Consolidated Sales	8.2%	5.2%	60.4%	0.1%	73.9%

		Americas	Europe	Asia & Oceania	Others	Total
1H 2018	Revenue to Customers Outside Japan	36,798	23,912	236,126	595	297,433
	Consolidated Revenue	/				402,532
	Ratio to Consolidated Sales	9.1%	5.9%	58.7%	0.1%	73.9%

Note: Major countries or regions excluding Japan are represented as follows:  
 Americas : U.S.A., Mexico, Brazil  
 Europe : Belgium, France, Germany, Sweden, Turkey  
 Asia & Oceania : China, Korea, Taiwan, Singapore, Malaysia, Hong Kong, Thailand  
 Others: African countries